ThinkPanmure Initiates Coverage on Idenix Pharmaceuticals (IDIX) with an Accumulate
More News related to IDIX
- Idenix Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
- Idenix Announces Data Presentations at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL)
- Idenix Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
- Idenix Pharma (IDIX) Posts Q4 Loss of $0.19, In-Line with Views
- Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
ThinkPanmure initiates coverage on Idenix Pharmaceuticals (Nasdaq: IDIX) with an Accumulate rating. Price target $6.
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.
Related Categories
New CoverageStocks Mentioned
-0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
